表观遗传疗法满足向蛋白质降解:癌症治疗中的HDAC-PROTACs
Md Sadique Hussain1,2, Liming Zhang3, Amita Joshi Rana4
1Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
Future medicinal chemistry
|July 16, 2025
概括
使用HDAC-PROTACs的表观遗传疗法提供了一种通过选择性降解激素脱乙酶 (HDACs) 的新型癌症治疗方法. 这些分子表现出强大的抗癌活性,并为精确瘤学提供了希望.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 基因组脱乙酶 (HDACs) 是关键的表观遗传调节剂,与癌症有关.
- 传统的HDAC抑制剂在选择性和有效性方面存在局限性.
- 有针对性的蛋白质降解提供了一种新的治疗方式.
研究的目的:
- 审查针对HDAC向蛋白解酶向嵌合体 (HDAC-PROTACs) 的开发和治疗潜力.
- 要突出HDAC-PROTACs相对于传统的HDAC抑制剂的优势.
- 讨论HDAC-PROTAC研究中的挑战和未来方向.
主要方法:
- 开发双功能分子 (PROTACs),这些分子可以将HDACs招募到E3连接酶中.
- 利用泛素-蛋白酶体系统进行选择性HDAC降解.
- 针对特定HDAC类 (I,IIa,IIb) 的PROTAC的设计.
主要成果:
- HDAC-PROTACs实现了目标HDACs的选择性降解,消除了酶和支架功能.
- 在临床前模型中,I,IIa和IIb类HDAC-PROTAC显示出强大的抗癌活性.
- PROTACs表现出催化活性,需要较低的剂量并提供持续的效果.
结论:
- HDAC-PROTACs代表了表观遗传疗法和精确瘤学的有前途的进步.
- 进一步优化选择性,交付和组合策略至关重要.
- 通过诱导向蛋白质降解,HDAC-PROTACs为癌症治疗提供了一种新的方法.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Histone Modification
3.6K
3.6K
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Chromatin Modification in iPS Cells
1.9K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.9K


